EP2115111B1 - Carboxylgruppen tragende benzophenon- oder benzoesäureanilid-derivate als enzymstabilisatoren - Google Patents

Carboxylgruppen tragende benzophenon- oder benzoesäureanilid-derivate als enzymstabilisatoren Download PDF

Info

Publication number
EP2115111B1
EP2115111B1 EP07847764.3A EP07847764A EP2115111B1 EP 2115111 B1 EP2115111 B1 EP 2115111B1 EP 07847764 A EP07847764 A EP 07847764A EP 2115111 B1 EP2115111 B1 EP 2115111B1
Authority
EP
European Patent Office
Prior art keywords
group
protease
amino
cooh
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07847764.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2115111A1 (de
Inventor
Andreas Michels
Robin Ghosh
Cornelius Bessler
Daniela Lowis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Priority to PL07847764T priority Critical patent/PL2115111T3/pl
Publication of EP2115111A1 publication Critical patent/EP2115111A1/de
Application granted granted Critical
Publication of EP2115111B1 publication Critical patent/EP2115111B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38663—Stabilised liquid enzyme compositions

Definitions

  • the present invention relates to detergents containing carboxyl-bearing benzophenone or benzoic acid anilide derivatives which act as protease inhibitors and are thus suitable enzyme stabilizers.
  • enzymes in detergents are well established in the art. They serve to extend the range of services of the funds concerned according to their specific activities. These include in particular hydrolytic enzymes such as proteases, amylases, lipases and cellulases. The first three hydrolyze proteins, starches and fats and thus contribute directly to Schmutzentfemung. Cellulases are used in particular because of their tissue effect.
  • hydrolytic enzymes such as proteases, amylases, lipases and cellulases.
  • the first three hydrolyze proteins, starches and fats and thus contribute directly to Schmutzentfemung.
  • Cellulases are used in particular because of their tissue effect.
  • Another group of detergent enzymes are oxidative enzymes, in particular oxidases, which, if appropriate, together with other components, preferably serve to bleach soiling or to produce the bleaching agents in situ.
  • enzymes which are subjected to constant optimization, further enzymes are constantly being made available for use in detergents, in order in particular to be able to optimally treat special soiling, such as, for example, pectinases, ⁇ -glucanases, mannanases or further hemicellulases for the hydrolysis of, in particular, special vegetable polymers.
  • special soiling such as, for example, pectinases, ⁇ -glucanases, mannanases or further hemicellulases for the hydrolysis of, in particular, special vegetable polymers.
  • proteases and in particular serine proteases, which include the subtilases. They cause the degradation of protein-containing stains on the items to be cleaned. However, they also hydrolyze themselves (autoproteolysis) and all other proteins contained in the agents concerned, i. especially other enzymes. This happens especially during the cleaning process, i. in the aqueous wash liquor, if comparatively favorable reaction conditions are present. However, this also happens during the storage of the respective agent, which is why with increasing storage time always a certain loss of enzyme activities, such as the protease activity, accompanied.
  • the enzyme activity in the detergent is inversely proportional to the storage time, with increasing storage time the enzyme activity decreases more and more. This is particularly problematic in gel or liquid and in particular in water-containing formulations, because in this with the water contained both the reaction medium and the hydrolysis reagent are available.
  • One goal in the development of detergents is therefore to stabilize the enzymes contained, especially during storage.
  • the protection understood against various unfavorable influences such as against denaturation or decay by physical influences or oxidation.
  • One focus of these developments is the protection of the contained proteins and / or enzymes against proteolytic cleavage. This can be done by the construction of physical barriers, such as by encapsulation of the enzymes in special enzyme granules or by packaging the means in two- or multi-chamber systems.
  • Another frequently approached approach is to add chemical compounds to the agents which inhibit the proteases and thus act collectively as stabilizers for the proteases and the other proteins and enzymes contained. It must be reversible protease inhibitors, since the protease activity is only temporarily, especially during storage, but not be suppressed during the cleaning process.
  • Polyols in particular glycerol and 1,2-propylene glycol, benzamidine hydrochloride, borax, boric acids, boronic acids or their salts or esters are established as reversible protease inhibitors in the prior art.
  • These include, in particular, derivatives with aromatic groups, for example ortho, meta or para-substituted phenylboronic acids, in particular 4-formylphenylboronic acid (4-FPBA) or the salts or esters of the abovementioned compounds.
  • 4-FPBA 4-formylphenylboronic acid
  • peptide aldehydes that is oligopeptides with reduced C-terminus, especially those of 2 to 50 monomers, are described for this purpose.
  • peptidic reversible protease inhibitors include ovomucoid and leupeptin.
  • specific, reversible peptide inhibitors and fusion proteins from proteases and specific peptide inhibitors are used for this purpose.
  • polyols such as glycerol and 1,2-propylene glycol have proved to be unfavorable due to their high concentrations of use necessary, because the other active ingredients of the respective agents can thus be contained only in proportionally smaller proportions.
  • Boric acid derivatives occupy an outstanding position among the serine protease inhibitors, which are effective at comparatively low concentrations.
  • the international patent application discloses WO 96/21716 A1 that acting as protease inhibitors boric acid derivatives are also suitable to stabilize enzymes in detergents.
  • a selection of particularly powerful stabilizers are disclosed in the international patent application WO 96/41859 A1 ,
  • boric acid derivatives have a decisive disadvantage.
  • a protease is to be understood as meaning all enzymes which are capable of hydrolyzing acid amide linkages of proteins.
  • the proteases are also detailed below.
  • the compound represented by the general structural formula is an aromatic compound having two benzene rings linked by a keto or an acid amide group according to the feature (a). It is thus a benzophenone or benzoic acid anilide derivative.
  • This benzophenone derivative can according to the features (b) and (c) in both rings as radicals R1, R2, R3, R4 and R5 (in ring 1) or R6, R7, R8, R9 and R10 (in ring 2) Hydrogen (H), a carboxyl (COOH), a methyl (CH 3 ), an ethyl (C 2 H 5 ), a hydroxyl (OH), a hydroxymethyl (CH 2 OH), an amino (NH) 2 ) and / or carry a halogen.
  • the prerequisite is that in each of the two rings at least one carboxyl group (COOH) is present.
  • rings 1 and 2 can be distinguished, ring 1 being the one which can be attributed to the benzoic acid or its substitution product, and ring 2 being the one which can be attributed to the aniline or its substitution product.
  • a benzophenone or benzoic acid anilide derivative which has in one of the two rings 1 or 2 as possible substituents two of the radicals R 1 to R 10 (A) and (B) which are ortho-stable with one another ( A) a mandatory or optionally further carboxyl group (COOH) mentioned in (b) and / or (c) and (B) are a hydroxymethyl group present as such groups or optionally as a grouping -CH 2 -O-CO- and thus together represent a five-membered lactone with the C atoms of the ring carrying them.
  • a mandatory or optionally further carboxyl group (COOH) mentioned in (b) and / or (c) and (B) are a hydroxymethyl group present as such groups or optionally as a grouping -CH 2 -O-CO- and thus together represent a five-membered lactone with the C atoms of the ring carrying them.
  • two of the substituents (A) and (B) according to (b) and (c) are a carboxyl group (COOH) or a hydroxymethyl group, respectively, in a ring immediately adjacent, ie orthostatic to each other and are present in the form of the hydroxyl group and the carboxymethyl group side by side.
  • these two groups together form a lactone and bind in lactone form to the protease to be inhibited. It is also possible that the binding takes place without prior formation of the lactone form.
  • the realization of the present invention to predetermine the lactone form during the synthesis and to add the already formed lactone as stabilizer to the agent in question.
  • the most suitable form is to be determined experimentally on the basis of the protease to be inhibited and of the envisaged stabilizer, which does not pose any fundamental difficulties for the person skilled in the art.
  • this lactone carboxyl group is counted as a carboxyl group according to feature (b) and (c), respectively but may also be present in addition to another, carboxyl group.
  • the present invention encompasses the compounds mentioned in all protonated and / or deprotonated forms.
  • the carboxyl group (s) (COOH) and optionally the amino group (s) (NH 2 ) are present depending on the pH of the surrounding medium as carboxylate (COO - ) or as ammonium groups (NH 3 + ).
  • carboxylate COO -
  • ammonium groups NH 3 +
  • oppositely charged cations H + , Na + , K + or the like
  • anions Cl - , Br - , formate, acetate, etc.
  • the present invention can be realized. Decisive in each case is the interaction between the invention-relevant compound and the invention to be inhibited / stabilizing protease.
  • the compounds relevant to the invention form a complex with the protease to be inhibited / stabilized according to the invention.
  • the active site of the protease is blocked by a compound which is not hydrolyzable by this enzyme and is not available for hydrolysis of other proteins present.
  • the equilibrium coefficient of this reaction is called the inhibition constant or K i .
  • the first advantage of the compounds relevant to the invention over the prior art, in addition to their lower volume requirement compared with the polyols, is that they have favorable inhibition constants with respect to the proteases which can be used in detergents. This applies, for example, to serine proteases, but also to metalloproteases.
  • the inhibitors thus bind reversibly, i. they do not interfere with solid and not too loose transient interactions with the enzyme.
  • the majority of the protease relevant to the invention is thus present during storage in the form of a protease-inhibitor complex.
  • the protease and possibly other proteins contained, in particular other enzymes are protected in this way against proteolysis by this enzyme (stabilized against proteolysis).
  • the binding equilibrium is shifted in the direction of dissociation, so that the complex dissolves and most of the protease protease protease is proteolytically active.
  • the compounds relevant to the invention are functioning protease inhibitors and thus enzyme stabilizers for detergents in accordance with the task formulated.
  • the second advantage of the invention relevant compounds over the prior art is that they have as elements only C, H, N and O and optionally halides and / or sulfur and in particular are free of boron. They thus do not form the undesirable boron by-products with other detergent ingredients.
  • the compounds mentioned are presumed to act as reversible inhibitors because they bind the substrate of the proteases, in particular with regard to the acid amide bond to be hydrolyzed, structurally same.
  • all proteases can be inhibited by the compounds relevant to the invention, so that they are suitable as protease inhibitors according to the invention.
  • serine proteases as has been shown with reference to the examples of the present application with the positive effect of the compounds experimentally described there on the basis of serine proteases, specifically subtilases, even more specific subtilisins, namely a variant of the subtilisin from Bacillus lentus DSM 5483.
  • the stabilizing compound is selected from one of the following stabilizers: structural formula Surname a) 2- (4-carboxybenzoyl) benzoic acid b) 3,3'-carbonyl-benzoic acid c) 2- (3-carboxybenzoyl) benzoic acid d) 4,4'-carbonylbis-benzoic acid e) 2,2'-carbonyl-benzoic acid f) 3- (4-carboxybenzoyl) benzoic acid G) 2 - [[(3-carboxyphenyl) amino] carbonyl] -benzoic acid H) 2 - [[(4-carboxyphenyl) amino] carbonyl] -benzoic acid i) 2 - [(2-carboxybenzoyl) amino] benzoic acid j) 2-amino-2 ', 4-carbonylbis-benzoic acid k) 3 - [[(4-carboxyphenyl) amino] carbony
  • Such detergents are preferred according to the invention in which the stabilizing compound has an inhibition constant (Ki) of 0.01 to 10 mM, preferably 0.1 to 5, particularly preferably 0.5 to 2, with respect to the protease contained.
  • Ki inhibition constant
  • [E], [I] and [EI] represent the respective molar equilibrium concentrations of enzyme (E), inhibitor (I) and the enzyme-inhibitor complex (EI). According to this definition, a substance with a small Ki is a good inhibitor under the respective test conditions.
  • K i The determination of K i is carried out on the basis of the activity test of the protease in the presence of the corresponding inhibitor.
  • the kinetics of invertin action, Biochem. Z. 49: 333-369 ), the enzymatic parameters K m , and k cat are determined in the presence of various concentrations of the inhibitor. For a Michaelis-Menten kinetics is simplified:
  • K l can be calculated using the Cheng-Prusoff equation ( Equation 2, Cheng Y., Prusoff WH (1973) Biochem. Pharmacol. 22, 3099-3108 ) are determined via the IC 50 value.
  • the determination of the IC 50 via the determination of the catalytic activity to a substrate in the presence of various concentrations of the inhibitor and the fitting of the experimental data to a sigmoidal dose-response with variable slope equation (pseudo-Hill slopes). It is the inhibitor concentration needed to achieve 50% inhibition.
  • K i IC 50 / 1 + S / K d
  • [S] is the substrate concentration in the assay and K d is the dissociation constant for the substrate, which at the IC 50 concentration of the inhibitor can be considered to be identical to K m for the substrate.
  • a protease namely the Bacillus lentus alkaline protease F49 (according to WO 95/23221 A1 ) in the presence of an inhibitor. Since this is a typical subtilisin protease, the values obtained with this enzyme are also typical of other serine proteases, in particular other subtilisin proteases. The exact value for a protease of interest must be determined in doubt on the basis of each specific protease.
  • the protease is in particular in a content of 2 .mu.g to 20 mg per g of the agent, preferably 5 .mu.g to 17.5 mg per g of the agent, more preferably from 20 ⁇ g to 15 mg per g of the agent, most preferably from 50 ⁇ g to 10 ⁇ g of the agent.
  • the stabilizer is contained in agents according to the invention in particular in a content of up to 50 mg per g of the agent, preferably up to 10 mg, more preferably up to 7 mg, most preferably up to 5 mg per g of the agent. Furthermore, it is preferred that the stabilizer in a content of 0.01 to 100 x K i (based on the protease contained), preferably 0.1 to 10 x K l more preferably 1 to 5 x K i is included.
  • the molar ratio of stabilizer to protease is preferably in the range from 1: 1 to 1000: 1, in particular from 1: 1 to 500: 1, particularly preferably from 1: 1 to 100: 1, very particularly preferably from 1: 1 to 20 :1.
  • an agent according to the invention may contain at least one further stabilizer.
  • the detergent is thus characterized in that it contains at least one further stabilizer.
  • these compounds act synergistically, ie the stabilization effect achieved by both compounds exceeds the sum of the two individual stabilization effects.
  • the stabilizer (s) is one or more polyols, in particular glycerol or 1,2-ethylene glycol, an antioxidant, lactate or one or more lactate derivatives or combinations thereof. It is likewise preferably one or more of those enzyme-stabilizing or inhibiting compounds which are described in the international patent applications WO 07/113241 A1 or WO 02/008398 are disclosed.
  • the protease stabilized or reversibly inhibited according to the invention is preferably a serine protease, in particular a subtilase, more preferably a subtilisin.
  • subtilisins BPN 'and Carlsberg examples of such proteases are the subtilisins BPN 'and Carlsberg, the protease PB92, the subtilisins 147 and 309, the alkaline protease from Bacillus lentus, subtilisin DY and the enzymes thermitase, proteinase K which can no longer be assigned to the subtilisins in the narrower sense and the proteases TW3 and TW7.
  • Subtilisin Carlsberg is available in a further developed form under the trade name Alcalase® from Novozymes A / S, Bagsv ⁇ rd, Denmark.
  • the subtilisins 147 and 309 are sold under the trade names Esperase®, and Savinase® by the company Novozymes. From the protease from Bacillus lentus DSM 5483 derived under the name BLAP® protease variants derived.
  • proteases are, for example, under the trade names Durazym ®, relase ®, Everlase® ®, Nafizym, Natalase ®, Kannase® ® and Ovozymes ® from Novozymes, under the trade names Purafect ®, Purafect ® OxP and Properase.RTM ® from Genencor , under the trade name Protosol® ® from Advanced Biochemicals Ltd., Thane, India, under the trade name Wuxi ® from Wuxi Snyder Bioproducts Ltd., China, under the trade names Proleather® ® and protease P ® from Amano Pharmaceuticals Ltd., Nagoya, Japan, and the enzyme available under the name Proteinase K-16 from Kao Corp., Tokyo, Japan.
  • proteases are particularly well stabilized or reversibly inhibited by the compounds described.
  • certain variants of proteases i. also variants of said proteases, stabilized by these compounds particularly advantageous.
  • Such protease variants are part of the invention described below.
  • a protease stabilized or reversibly inhibited according to the invention can be a wild-type enzyme or a protease variant.
  • wild-type enzyme is to be understood that the enzyme is present in a naturally occurring organism or in a natural habitat can be isolated from this.
  • enzymes are modifiable and sometimes selectively modified, in particular in order to adapt their properties to the intended uses or to influence their catalytic activity. These changes often occur by altering the amino acid sequence of the enzyme. Such changes can be targeted and thus local or random, for example, by random mutagenesis done.
  • An enzyme variant is understood as meaning enzymes which have been generated from an initial enzyme, for example a wild-type enzyme, by altering the amino acid sequence.
  • the alteration of the amino acid sequence is preferably carried out by mutations, wherein amino acid substitutions, deletions, insertions or combinations thereof may be made.
  • the incorporation of such mutations into proteins is well known in the art and to those skilled in the art of enzyme technology. In principle, all enzymes can be changed in this way.
  • Protease variants are preferred according to the invention. These were generated from an initial protease, for example a wild-type protease, by altering the amino acid sequence, preferably amino acid substitutions, deletions, insertions or combinations thereof.
  • the starting protease does not necessarily have to be a naturally occurring wild-type protease; a protease known from the prior art in which changes have already been made can also be further developed and therefore again serve as an initial protease for generating further protease variants.
  • all of the proteases described above may be used unchanged in agents according to the invention and be stabilized by the compounds described.
  • they can also be the starting enzyme for a variant which is then contained in an agent according to the invention and stabilized by the compounds described.
  • the detergent is therefore characterized in that the protease has been obtained from an initial protease by at least one change of an amino acid, the change being a substitution, insertion or deletion of an amino acid, and at least to the starting protease at the amino acid level 90%, preferably at least 92.5%, more preferably at least 95%, and most preferably at least 97.5% is identical.
  • sequence comparisons are known to the person skilled in the art of enzyme technology.
  • sequence comparisons for example, the identity or homology values are determined for sequences to be compared.
  • Such a comparison is accomplished by associating similar sequences in the nucleotide or amino acid sequences of the proteins of interest. This is called homologization.
  • a tabular assignment of the respective positions is referred to as alignment.
  • alignments are created using computer programs, such as the algorithms FASTA or BLAST; This procedure is for example by DJ Lipman and WR Pearson (1985) in Science, Vol. 227, pp. 1435-1441 described.
  • a summary of all matching positions in the compared sequences is called a consensus sequence.
  • Such a comparison also allows a statement about the similarity or homology of the compared sequences to each other. This is represented in percent identity, that is the proportion of identical nucleotides or amino acid residues at the same or in an alignment corresponding positions. A broader concept of homology includes the conserved amino acid substitutions in this value. It then speaks of percent similarity. Such statements can be made about whole proteins or genes or only over individual areas.
  • homologous regions of different proteins are defined by matches in amino acid sequence. These can also be identified by identical function. It goes as far as complete identities in the smallest areas, so-called boxes, which contain only a few amino acids and usually perform essential functions for the overall activity.
  • the functions of the homologous regions are to be understood as the smallest partial functions of the function carried out by the entire protein, such as, for example, the formation of individual hydrogen bonds for the complexation of a substrate or transition complex.
  • sequence comparisons or alignments also serve to determine mutually corresponding positions in different molecules.
  • positions in the respective amino acid or nucleic acid sequence correspond to one another, even if the respective sequences have, for example, different total lengths or different domains or partial sequences or if additional amino acids or nucleotides are present within a sequence are.
  • a specific position in a first sequence can therefore be concretely assigned to a corresponding position in a second sequence, whereby it is quite possible for the positions corresponding to one another to be located at different locations in the molecule.
  • different amino acid residues may be present at the corresponding positions. Therefore, for such sequence comparisons or for determining a Specifically stated position, which position it is and which enzyme is assumed, that is, which counting method of determining position is to be based.
  • the amino acid sequence of the mature protein of the alkaline protease from Bacillus lentus DSM 5483 is used for determining the position, which is described in International Published Patent Application WO 91/02792 A1 and has a length of 269 amino acid residues (referred to in the present application as Bacillus lentus alkaline protease).
  • the detergent is characterized in that the protease was obtained from an initial protease by at least one change of an amino acid, the change being a substitution or insertion of an amino acid in that region of the amino acid sequence corresponding to positions 95 to 103 of the amino acid sequence Assigned alkaline protease from Bacillus lentus in an alignment.
  • Such a protease variant is particularly preferably a variant with an insertion of a single amino acid according to one or more of the positions 95, 96, 97, 98, 99, 100, 101, 102 and / or 103 and very particularly preferably between positions 97 and 98 and / or positions 99 and 100.
  • the detergent is characterized in that the protease has been obtained from an initial protease by at least one modification of an amino acid corresponding to the positions 3, 4, 36, 42, 43, 47, 56, 61, 69, 87, 96, 99, 101, 102, 104, 114, 118, 120, 130, 139, 141, 142, 154, 157, 188, 193, 199, 205, 211, 224, 229, 236, 237, 242, 243, 250, 253, 255 and 268 of the Bacillus lentus alkaline protease are associated in an alignment, wherein the alteration is a substitution, insertion or deletion of an amino acid.
  • an amino acid change relative to the parent molecule occurs in one or more of the following positions: 3, 4, 43, 61, 188, 193, 199, 211, 224, 250 and 253 (count according to Bacillus lentus alkaline protease), more preferably with one or more of the amino acid substitutions X3T, X4I, X43V, X61A, X188P, X193M, X199I, X211L, X211D, X211E, X211G, X211N or X211Q, X224V, X250G and / or X253N.
  • the protease is a variant with a point mutation at position 211, preferably with a substitution of a single amino acid in this position, more preferably with the amino acid substitution X211 L.
  • the above positional information relates in turn to those amino acid residues which are assigned to said positions of the alkaline protease from Bacillus lentus in an alignment.
  • Agents according to the invention may contain, in addition to the protease, one or more further enzymes, in particular from the following group: one or more further proteases, amylases, hemicellulases, cellulases, lipases and oxidoreductases.
  • the amylase is preferably an ⁇ -amylase.
  • the hemicellulase is preferably a ⁇ -glucanase, a pectinase, a pullulanase and / or a mannanase.
  • the cellulase is preferably a cellulase mixture or a one-component cellulase, preferably or predominantly an endoglucanase and / or a cellobiohydrolase.
  • the oxidoreductase is preferably an oxidase, in particular a choline oxidase, or a perhydrolase.
  • Agents according to the invention preferably comprise at least one complexing agent and / or builder substances, the builder being in particular a zeolite builder, and / or a nonionic surfactant, the nonionic surfactant preferably being a hydroxy mixed ether, and / or optical Brightener, wherein the optical brightener is diphenyl compounds, in particular distyryl biphenyl derivatives, and / or stilbentriazine derivatives.
  • V1 is the strongest and thus most suitable protease inhibitor or stabilizer, followed by V2, V3, V4 (practically as good as V3) and V5.
  • these compounds are also suitable for stabilizing the enzymatic activities in protease-containing detergents and cleaning agents during storage.
  • a liquid detergent was prepared with the following composition (all figures in percent by weight): 0.3-0.5% xanthan gum, 0.2-0.4% anti-foaming agent, 6-7% glycerol, 0.3 -0.5% ethanol, 4-7% FAEOS, 24-28% nonionic surfactants, 1% boric acid, 1-2% sodium citrate (dihydrate), 2-4% soda, 14-16% coconut fatty acids, 0.5 % HEDP, 0-0.4% PVP, 0-0.05% optical brightener, 0-0.001% dye, balance: demineralized water.
  • the initial values for the proteolytic activity of the agent in question were compared with the values determined after storage. The higher the activity remaining after storage, the better the protease contained was inactivated during storage and the better the compound in question is suitable as a stabilizer according to the invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
EP07847764.3A 2007-03-06 2007-12-04 Carboxylgruppen tragende benzophenon- oder benzoesäureanilid-derivate als enzymstabilisatoren Not-in-force EP2115111B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL07847764T PL2115111T3 (pl) 2007-03-06 2007-12-04 Przenoszące grupy hydroksylowe pochodne benzofenonu lub anilidu kwasu benzoesowego jako stabilizatory enzymów

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007011236A DE102007011236A1 (de) 2007-03-06 2007-03-06 Carboxylgruppen tragende Benzophenon-oderBenzoesäureanilid-Derivate als Enzymstabilisatoren
PCT/EP2007/063260 WO2008107030A1 (de) 2007-03-06 2007-12-04 Carboxylgruppen tragende benzophenon- oder benzoesäureanilid-derivate als enzymstabilisatoren

Publications (2)

Publication Number Publication Date
EP2115111A1 EP2115111A1 (de) 2009-11-11
EP2115111B1 true EP2115111B1 (de) 2014-04-30

Family

ID=39045549

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07847764.3A Not-in-force EP2115111B1 (de) 2007-03-06 2007-12-04 Carboxylgruppen tragende benzophenon- oder benzoesäureanilid-derivate als enzymstabilisatoren

Country Status (7)

Country Link
US (1) US7968508B2 (pl)
EP (1) EP2115111B1 (pl)
JP (1) JP2010520336A (pl)
DE (1) DE102007011236A1 (pl)
ES (1) ES2471447T3 (pl)
PL (1) PL2115111T3 (pl)
WO (1) WO2008107030A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1807498B2 (de) † 2004-11-02 2019-02-20 Henkel AG & Co. KGaA Herstellungsverfahren für granulate / agglomerate für wasch- oder reinigungsmittel
DE102010038501A1 (de) * 2010-07-27 2012-02-02 Henkel Ag & Co. Kgaa Stabilisierte flüssige enzymhaltige Tensidzubereitung
EP3559227B1 (en) 2016-12-21 2025-02-19 Danisco US Inc. Protease variants and uses thereof
WO2018118950A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
WO2019108599A1 (en) 2017-11-29 2019-06-06 Danisco Us Inc Subtilisin variants having improved stability
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
EP3799601A1 (en) 2018-06-19 2021-04-07 Danisco US Inc. Subtilisin variants
CN113166682A (zh) 2018-09-27 2021-07-23 丹尼斯科美国公司 用于医疗器械清洁的组合物
EP3887515A1 (en) 2018-11-28 2021-10-06 Danisco US Inc. Subtilisin variants having improved stability
WO2020242858A1 (en) 2019-05-24 2020-12-03 Danisco Us Inc Subtilisin variants and methods of use
CN112458070B (zh) * 2020-10-26 2021-07-06 林小丽 用于污泥处理的酶制剂
CN112280768B (zh) * 2020-10-26 2021-07-06 林小丽 碱性蛋白酶低温突变体及其在污泥处理中的应用
EP4448750A2 (en) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisin variants and uses thereof
WO2023114936A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
CN118679252A (zh) 2021-12-16 2024-09-20 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
CN118369413A (zh) 2021-12-16 2024-07-19 宝洁公司 包含淀粉酶的家庭护理组合物
CA3240641A1 (en) 2021-12-16 2023-06-22 Michelle Jackson Automatic dishwashing composition comprising a protease
WO2023114794A1 (en) 2021-12-16 2023-06-22 The Procter & Gamble Company Fabric and home care composition comprising a protease
US20230272310A1 (en) 2021-12-16 2023-08-31 The Procter & Gamble Company Home care composition
DE102022205591A1 (de) * 2022-06-01 2023-12-07 Henkel Ag & Co. Kgaa Wasch- und reinigungsmittel mit verbesserter enzymstabilität
DE102022205588A1 (de) * 2022-06-01 2023-12-07 Henkel Ag & Co. Kgaa Wasch- und reinigungsmittel mit verbesserter enzymstabilität
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
EP4581138A1 (en) 2022-09-02 2025-07-09 Danisco US Inc. Subtilisin variants and methods related thereto
WO2024102698A1 (en) 2022-11-09 2024-05-16 Danisco Us Inc. Subtilisin variants and methods of use
EP4658776A1 (en) 2023-02-01 2025-12-10 Danisco US Inc. Subtilisin variants and methods of use
EP4677080A1 (en) 2023-03-06 2026-01-14 Danisco US Inc. Subtilisin variants and methods of use
WO2025018894A1 (en) 2023-07-19 2025-01-23 Rijksuniversiteit Groningen Bio-renewable surfactants based on fructose and fatty acid esters.
WO2026024921A1 (en) 2024-07-25 2026-01-29 The Procter & Gamble Company Detergent composition comprising a subtilisin variant and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8900496D0 (en) * 1989-01-10 1989-03-08 Procter & Gamble Liquid detergent composition containing enzyme and enzyme stabilization system
DE69033388T2 (de) 1989-08-25 2000-05-11 Henkel Research Corp., Santa Rosa Alkalisches proteolytisches enzym und verfahren zur herstellung
NZ237570A (en) 1990-04-13 1993-09-27 Colgate Palmolive Co Enzyme stabilising composition and stabilised enzyme-containing built detergent compositions
EP0478050A1 (en) 1990-09-24 1992-04-01 Unilever N.V. Detergent composition
CZ230593A3 (en) 1991-04-30 1994-04-13 Procter & Gamble Liquid detergents with arylboric acid
EP0511456A1 (en) 1991-04-30 1992-11-04 The Procter & Gamble Company Liquid detergents with aromatic borate ester to inhibit proteolytic enzyme
AU3151293A (en) 1991-12-04 1993-06-28 Procter & Gamble Company, The Liquid laundry detergents with citric acid, cellulase, and boric-diol complex to inhibit proteolytic enzyme
US5840677A (en) 1993-07-09 1998-11-24 Novo Nordisk A/S Boronic acid or borinic acid derivatives as enzyme stabilizers
WO1995023221A1 (en) 1994-02-24 1995-08-31 Cognis, Inc. Improved enzymes and detergents containing them
US5834415A (en) 1994-04-26 1998-11-10 Novo Nordisk A/S Naphthalene boronic acids
AU4328396A (en) 1995-01-09 1996-07-31 Novo Nordisk A/S Stabilization of liquid enzyme compositions
CN1103810C (zh) 1995-06-13 2003-03-26 诺沃奇梅兹有限公司 含苯基硼酸衍生物酶稳定剂的液冻组合物
RU2157146C2 (ru) 1995-06-13 2000-10-10 ВИЛЬЯМ КУК Европа, A/S Устройство для имплантации в сосудах и полых органах (его варианты)
US5741767A (en) 1995-11-16 1998-04-21 Lever Brothers Company, Division Of Conopco, Inc. Peracid based dishwashing detergent composition
WO1998022567A1 (en) * 1996-11-18 1998-05-28 Alcon Laboratories, Inc. Stable liquid enzyme compositions for cleaning contact lenses
AU2001277957A1 (en) 2000-07-22 2002-02-05 Genencor International, Inc. Stabilization of enzymes
DE10360805A1 (de) 2003-12-23 2005-07-28 Henkel Kgaa Neue Alkalische Protease und Wasch- und Reinigungsmittel, enthaltend diese neue Alkalische Protease
DE102004019751A1 (de) 2004-04-23 2005-11-17 Henkel Kgaa Neue Alkalische Proteasen und Wasch- und Reinigungsmittel, enthaltend diese neuen Alkalischen Proteasen
DE102005028295A1 (de) 2005-06-18 2006-11-16 Henkel Kgaa Proteasen aus psychrophilen Organismen
WO2007113241A1 (en) 2006-03-31 2007-10-11 Novozymes A/S A stabilized liquid enzyme composition

Also Published As

Publication number Publication date
PL2115111T3 (pl) 2014-09-30
US20100062964A1 (en) 2010-03-11
ES2471447T3 (es) 2014-06-26
EP2115111A1 (de) 2009-11-11
JP2010520336A (ja) 2010-06-10
DE102007011236A1 (de) 2008-09-11
WO2008107030A1 (de) 2008-09-12
US7968508B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
EP2115111B1 (de) Carboxylgruppen tragende benzophenon- oder benzoesäureanilid-derivate als enzymstabilisatoren
EP2220204B1 (de) Waschmittel mit stabilisierten enzymen
EP2188360A1 (de) Polycyclische verbindungen als enzymstabilisatoren
EP2313482B2 (de) Verfahren zur verbesserung der reinigungsleistung eines wasch- oder reinigungsmittels
DE102008014760A1 (de) Imidazolium-Salze als Enzymstabilisatoren
EP3380598B1 (de) Enzymstabilisatoren
EP2655587B1 (de) Flüssige tensidzubereitung enthaltend lipase und phosphonat
WO2016087181A1 (de) Enzymstabilisatoren
WO2016180659A1 (de) Enzymstabilisatoren
WO2017072111A1 (de) Enzymstabilisatoren
DE102008010429A1 (de) Harnstoff-Derivate als Enzymstabilisatoren
WO2017207546A1 (de) Stabilisierte enzym-haltige wasch- und reinigungsmittel
EP3227424A1 (de) Enzymstabilisatoren
EP4532665A1 (de) Wasch- und reinigungsmittel mit verbesserter enzymstabilität
WO2023232193A1 (de) Wasch- und reinigungsmittel mit verbesserter enzymstabilität
WO2016087184A1 (de) Enzymstabilisatoren
EP3226872A1 (de) Enzymstabilisatoren
DE102023204055A1 (de) Leistungsverbesserte protease-varianten
EP2598622A2 (de) Stabilisierte flüssige enzymhaltige tensidzubereitung
WO2017089163A1 (de) Enzymstabilisatoren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090814

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20100503

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131121

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 665180

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502007013051

Country of ref document: DE

Effective date: 20140612

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2471447

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140626

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140731

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140730

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140830

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502007013051

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150202

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502007013051

Country of ref document: DE

Effective date: 20150202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141204

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20141204

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141231

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141204

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141204

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141231

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 665180

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141204

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20071204

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20171221

Year of fee payment: 11

Ref country code: DE

Payment date: 20171211

Year of fee payment: 11

Ref country code: CZ

Payment date: 20171201

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20171123

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20180123

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20171221

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502007013051

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190702

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181204

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181204